Tianmao Group: Tianmao Industrial Group Co., Ltd. voluntary information disclosure announcement on the premium income of Guohua Life Insurance Co., Ltd.
Tianmao Group: Announcement on the appointment of the company\'s senior management and other personnel
Tianmao Group: Semi-annual Non-Operating Capital Occupancy and Other Related Capital Transactions Summary
Tianmao Group: 2024 Semi-Annual Financial Report
Tianmao Group: Semi-Annual Financial Report
Tianmao Group: Legal Opinion of Tianmao Group\'s 2024 Third Extraordinary General Meeting of Shareholders
Tianmao Group: Announcement of Resolutions of the 2024 Third Extraordinary General Meeting of Shareholders
Tianmao Group: Announcement on the completion of the general election of the Board of Directors and the Board of Supervisors
Hubei Biocause Pharmaceutical: Tianmao Industrial Group Co., Ltd. voluntary information disclosure announcement regarding the premium income of China Best Life Insurance Co., Ltd.
Hubei Biocause Pharmaceutical: Announcement Regarding Revision of the Articles of Association, Shareholders' Meeting Rules, Board of Directors Meeting Rules, and Board of Supervisors Meeting Rules.
Hubei Biocause Pharmaceutical: The board of directors nomination committee of Hubei Biocause Pharmaceutical's 9th session has reviewed the qualifications of director candidates.
Hubei Biocause Pharmaceutical: Announcement Regarding the Election of Employee Representatives to the Tenth Supervisory Board
Hubei Biocause Pharmaceutical: Board of Directors Meeting Rules (August 2024)
Hubei Biocause Pharmaceutical: Notice about convening the third temporary shareholders' meeting in 2024.
Hubei Biocause Pharmaceutical: Tianmao Industrial Group Co., Ltd. voluntary information disclosure announcement regarding the premium income of China Best Life Insurance Co., Ltd.
Hubei Biocause Pharmaceutical: Announcement of the resolutions of the second extraordinary general meeting of shareholders for the year 2024.
Hubei Biocause Pharmaceutical: Announcement on Repurchasing Shares for Cancellation and Reduction of Registered Capital and Notifying Creditors.
Hubei Biocause Pharmaceutical: Legal opinion for the second extraordinary shareholders meeting of Hubei Biocause Pharmaceutical in 2024.
Hubei Biocause Pharmaceutical: Announcement from Hubei Biocause Pharmaceutical regarding the resignation of company directors and senior management.
Hubei Biocause Pharmaceutical: Announcement regarding the appointment of senior management personnel in the company.
No Data
No Data